Deutsche Bank AG Purchases Shares of 224,145 Ocular Therapeutix, Inc. $OCUL

Deutsche Bank AG purchased a new position in shares of Ocular Therapeutix, Inc. (NASDAQ:OCUL) in the second quarter, according to its most recent filing with the SEC. The firm purchased 224,145 shares of the biopharmaceutical company’s stock, valued at approximately $2,201,000.

Several other hedge funds have also recently made changes to their positions in OCUL. Trust Co. of Vermont acquired a new position in Ocular Therapeutix in the second quarter valued at approximately $112,000. Hikari Power Ltd bought a new stake in shares of Ocular Therapeutix in the 2nd quarter valued at $167,000. Bank of New York Mellon Corp bought a new stake in shares of Ocular Therapeutix in the 2nd quarter valued at $5,433,000. GSA Capital Partners LLP acquired a new position in shares of Ocular Therapeutix during the 2nd quarter valued at $262,000. Finally, E. Ohman J or Asset Management AB boosted its stake in Ocular Therapeutix by 28.3% during the second quarter. E. Ohman J or Asset Management AB now owns 385,000 shares of the biopharmaceutical company’s stock worth $3,781,000 after acquiring an additional 85,000 shares in the last quarter. 59.21% of the stock is owned by institutional investors.

Ocular Therapeutix Trading Up 0.5%

NASDAQ:OCUL opened at $10.82 on Friday. The company has a debt-to-equity ratio of 0.14, a current ratio of 13.10 and a quick ratio of 13.03. The firm has a 50-day moving average of $9.66 and a 200-day moving average of $9.16. The company has a market cap of $2.38 billion, a PE ratio of -7.62 and a beta of 0.93. Ocular Therapeutix, Inc. has a one year low of $6.23 and a one year high of $16.44.

Ocular Therapeutix (NASDAQ:OCUL) last announced its quarterly earnings results on Monday, August 3rd. The biopharmaceutical company reported ($0.35) earnings per share for the quarter, beating the consensus estimate of ($0.40) by $0.05. The business had revenue of $13.47 million for the quarter, compared to analysts’ expectations of $13.20 million. Ocular Therapeutix had a negative net margin of 579.10% and a negative return on equity of 59.89%. The firm’s revenue for the quarter was down .1% compared to the same quarter last year. During the same quarter last year, the firm earned ($0.39) EPS. As a group, equities research analysts expect that Ocular Therapeutix, Inc. will post -1.47 EPS for the current fiscal year.

Insider Transactions at Ocular Therapeutix

In other news, insider Pravin Dugel sold 21,649 shares of the stock in a transaction that occurred on Monday, August 24th. The stock was sold at an average price of $10.77, for a total value of $233,159.73. Following the completion of the sale, the insider directly owned 2,525,429 shares of the company’s stock, valued at $27,198,870.33. This represents a 0.85% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Peter Kaiser sold 3,035 shares of the firm’s stock in a transaction that occurred on Monday, August 24th. The shares were sold at an average price of $10.77, for a total value of $32,686.95. Following the completion of the transaction, the insider owned 264,378 shares in the company, valued at $2,847,351.06. This represents a 1.13% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold a total of 29,877 shares of company stock valued at $321,827 over the last ninety days. 3.10% of the stock is currently owned by insiders.

Wall Street Analyst Weigh In

A number of equities research analysts have commented on the stock. Chardan Capital restated a “buy” rating and issued a $23.00 price target on shares of Ocular Therapeutix in a report on Tuesday, August 4th. Royal Bank Of Canada reissued an “outperform” rating and set a $30.00 price objective on shares of Ocular Therapeutix in a research report on Wednesday, May 6th. Zacks Research upgraded Ocular Therapeutix from a “strong sell” rating to a “hold” rating in a research note on Wednesday, August 12th. Wall Street Zen raised Ocular Therapeutix from a “sell” rating to a “hold” rating in a research report on Saturday, August 8th. Finally, Robert W. Baird upped their price target on Ocular Therapeutix from $24.00 to $30.00 and gave the stock an “outperform” rating in a research note on Thursday, June 18th. Eleven equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $25.75.

About Ocular Therapeutix

Ocular Therapeutix, Inc is a biopharmaceutical company dedicated to the development of innovative therapies for diseases and conditions of the eye. Founded in 2011 and headquartered in Bedford, Massachusetts, the company focuses on sustained-release drug delivery platforms designed to address key unmet needs in ophthalmology. Its proprietary hydrogel-based inserts and sealants aim to improve patient compliance and outcomes by providing controlled release of active pharmaceutical ingredients directly to ocular tissues.

The company’s flagship product, DEXTENZA®, is a preservative-free, sustained-release dexamethasone intracanalicular insert approved by the U.S.